{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:13:23Z","timestamp":1786997603143,"version":"build-2736575974"},"reference-count":41,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","trasci.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion and Apheresis Science"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.transci.2022.103359","type":"journal-article","created":{"date-parts":[[2022,1,20]],"date-time":"2022-01-20T02:35:38Z","timestamp":1642646138000},"page":"103359","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Comparison of transfusion-outcome in patients with massive bleeding receiving pathogen-reduced platelets prepared with two different technologies"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9049-1987","authenticated-orcid":false,"given":"Carina","family":"Arcas Otero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Pereira Saavedra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azucena","family":"Castrillo Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00aa Dolores","family":"Vilari\u00f1o L\u00f3pez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.transci.2022.103359_bib0005","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/php.12311","article-title":"Chemical and biological mechanisms of pathogen reduction technologies","volume":"90","author":"Mundt","year":"2014","journal-title":"Photochem Photobiol"},{"key":"10.1016\/j.transci.2022.103359_bib0010","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1111\/j.0041-1132.2005.04316.x","article-title":"Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light","volume":"45","author":"Lin","year":"2005","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2022.103359_bib0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000323937","article-title":"Pathogen inactivation of platelet and plasma blood components for transfusion using the INTERCEPT blood systemTM","volume":"38","author":"Irsch","year":"2011","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.transci.2022.103359_bib0020","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000324160","article-title":"Pathogen reduction technology treatment of platelets, plasma and whole blood using Riboflavin and UV light","volume":"38","author":"Marschner","year":"2011","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.transci.2022.103359_bib0025","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1537-2995.2012.03715.x","article-title":"Treatment of whole blood with ribo\ufb02avin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease?","volume":"53","author":"Fast","year":"2013","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2022.103359_bib0030","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/bmt.2009.124","article-title":"Irradiation eradication and pathogen reduction. Ceasing cesium irradiation of blood products","volume":"44","author":"Mintz","year":"2009","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.transci.2022.103359_bib0035","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1111\/j.1537-2995.2010.02714.x","article-title":"White blood cell inactivation after treatment with riboflavin and ultraviolet light","volume":"50","author":"Marschner","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2022.103359_bib0040","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1111\/trf.14930","article-title":"Transfusion-associated graft-versus-host disease reexamined: potential for improved prevention using a universally applied intervention","volume":"58","author":"Kleinman","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2022.103359_bib0045","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1111\/trf.14589","article-title":"Amotosalen\/UVA treatment inactivates T cells more effectively than the recommended gamma dose for prevention of transfusion-associated graft-versus-host disease","volume":"58","author":"Castro","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2022.103359_bib0050","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1182\/blood-2002-03-0932","article-title":"Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial","volume":"101","author":"Van Rhenen","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.transci.2022.103359_bib0055","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1182\/blood-2003-12-4443","article-title":"Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial","volume":"104","author":"McCullough","year":"2004","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.transci.2022.103359_bib0060","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1182\/blood-2018-02-831289","article-title":"Hemostatic efficacy of pathogen-inactivated- versus untreated- platelets: a randomized controlled trial","volume":"132","author":"Van der Meer","year":"2018","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.transci.2022.103359_bib0065","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1111\/trf.14042","article-title":"Clinical effectiveness of platelets in additive solution treated with two commercial pathogen-reduction technologies","volume":"57","author":"Rebulla","year":"2017","journal-title":"Transfusion"},{"issue":"11","key":"10.1016\/j.transci.2022.103359_bib0070","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1537-2995.2010.02694.x","article-title":"A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology","volume":"50","author":"Mirasol Clinical Evaluation Study Group","year":"2010","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2022.103359_bib0075","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/j.1365-2141.2011.08635.x","article-title":"A multi-centre study of therapeutic ef\ufb01cacy and safety of platelet components treated with amotosalen and ultraviolet A pathogen inactivation stored for 6 or 7 d prior to transfusion","volume":"153","author":"Lozano","year":"2011","journal-title":"Br J Haematol"},{"key":"10.1016\/j.transci.2022.103359_bib0080","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1423-0410.2011.01555.x","article-title":"Meta-analysis of the studies of bleeding complications of platelets pathogen-reduced with the Intercept system","volume":"102","author":"Vamvakas","year":"2012","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2022.103359_bib0085","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1111\/j.1423-0410.2012.01614.x","article-title":"Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials","volume":"103","author":"Cid","year":"2012","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2022.103359_bib0090","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/j.1365-2141.2010.08227.x","article-title":"Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction","volume":"150","author":"Kerkhoffs","year":"2010","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.transci.2022.103359_bib0095","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1001\/jamaoncol.2017.5123","article-title":"Comparison of the hemostatic efficacy of pathogen-reduced platelets vs untreated platelets in patients with thrombocytopenia and malignant hematologic diseases","volume":"4","author":"Garban","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.transci.2022.103359_bib0100","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1111\/vox.12489","article-title":"Patient outcomes and amotosalen\/UVA-treated platelet utilization in massively transfused patients","volume":"112","author":"Nussbaumer","year":"2017","journal-title":"Vox Sang"},{"issue":"5","key":"10.1016\/j.transci.2022.103359_bib0105","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1111\/trf.14043","article-title":"Pathogen inactivation treatment of plasma and platelet concentrates and their predicted functionality in massive transfusion protocols","volume":"57","author":"Arbaeen","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2022.103359_bib0110","first-page":"153","article-title":"Modelling the effects of blood component storage lesions on the quality of haemostatic resuscitation in massive transfusion for trauma","volume":"15","author":"Mays","year":"2017","journal-title":"Blood Transfus"},{"issue":"6","key":"10.1016\/j.transci.2022.103359_bib0115","doi-asserted-by":"crossref","first-page":"1760","DOI":"10.1213\/ane.0b013e3181a0b6c6","article-title":"Transfusion management of trauma patients","volume":"108","author":"Shaz","year":"2009","journal-title":"Anesth Analg"},{"key":"10.1016\/j.transci.2022.103359_bib0120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/vox.12121","article-title":"Elucidating the clinical characteristics of patients captured using different definitions of massive transfusion","volume":"107","author":"Zatta","year":"2014","journal-title":"Vox Sang"},{"issue":"8","key":"10.1016\/j.transci.2022.103359_bib0125","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.medin.2015.05.002","article-title":"Multidisciplinary consensus document on the management of massive haemorrhage (HEMOMAS document)","volume":"39","author":"Llau","year":"2015","journal-title":"Med Intensiva"},{"key":"10.1016\/j.transci.2022.103359_bib0130","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.transci.2022.103359_bib0135","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/tme.12434","article-title":"Aetiology and outcome of massive transfusion in two large London teaching hospitals over a 3-year period (2012\u20132014)","volume":"27","author":"Green","year":"2017","journal-title":"Transfus Med"},{"key":"10.1016\/j.transci.2022.103359_bib0140","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/vox.12487","article-title":"Descriptive characteristics and in-hospital mortality of critically bleeding patients requiring massive transfusion: results from the Australian and New Zealand Massive Transfusion Registry","volume":"112","author":"Ruseckaite","year":"2017","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2022.103359_bib0145","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/j.tracli.2017.04.005","article-title":"Age of blood and survival after massive transfusion","volume":"24","author":"Sanz","year":"2017","journal-title":"Transfus Clin Biol"},{"issue":"6","key":"10.1016\/j.transci.2022.103359_bib0150","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1001\/jamasurg.2017.0098","article-title":"Association between ratio of fresh frozen plasma to red blood cells during massive transfusion and survival among patients without traumatic injury","volume":"152","author":"Mesar","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.transci.2022.103359_bib0155","first-page":"280","article-title":"Haemostatic function measured by thromboelastography and metabolic activity of platelets treated with riboflavin and UV light","volume":"18","author":"Ballester-Servera","year":"2020","journal-title":"Blood Transfus"},{"key":"10.1016\/j.transci.2022.103359_bib0160","doi-asserted-by":"crossref","first-page":"103529","DOI":"10.1016\/j.jprot.2019.103529","article-title":"Proteomic analysis of extracellular vesicles derived from platelet concentrates treated with Mirasol\u00ae identifies biomarkers of platelet storage lesion","volume":"210","author":"Hermida-Nogueira","year":"2020","journal-title":"J Proteomics"},{"key":"10.1016\/j.transci.2022.103359_bib0165","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/trf.13512","article-title":"Will pathogen reduction of blood components harm more people than it helps in developed countries?","volume":"56","author":"Hess","year":"2016","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2022.103359_bib0170","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1111\/trf.14797","article-title":"Our experience in riboflavin and ultraviolet light pathogen reduction technology for platelets: from platelet production to patient care","volume":"58","author":"Jimenez-Marco","year":"2018","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2022.103359_bib0175","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1537-2995.2010.02873.x","article-title":"Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period","volume":"51","author":"Cazenave","year":"2011","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2022.103359_bib0180","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1111\/vox.12456","article-title":"Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Care","volume":"112","author":"Amato","year":"2017","journal-title":"Vox Sang"},{"key":"10.1016\/j.transci.2022.103359_bib0185","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1111\/trf.15511","article-title":"Clinical impact of amotosalen-ultraviolet A pathogen-inactivated platelets stored for up to 7 days","volume":"59","author":"Infanti","year":"2019","journal-title":"Transfusion"},{"key":"10.1016\/j.transci.2022.103359_bib0190","article-title":"Pathogen-reduced platelets for the prevention of bleeding (Review)","volume":"7","author":"Estcourt","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.transci.2022.103359_bib0195","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000487513","article-title":"Platelet additive solutions: a review of the latest developments and their clinical implications","volume":"45","author":"Van der Meer","year":"2018","journal-title":"Transfus Med Hemother"},{"key":"10.1016\/j.transci.2022.103359_bib0200","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1111\/tme.12524","article-title":"Massive transfusions for critical bleeding: is everything old new again?","volume":"28","author":"Flint","year":"2018","journal-title":"Transfus Med"},{"key":"10.1016\/j.transci.2022.103359_bib0205","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.tmrv.2017.06.003","article-title":"Optimal dose, timing and ratio of blood products in massive transfusion: results from a systematic review","volume":"32","author":"McQuilten","year":"2018","journal-title":"Transfus Med Rev"}],"container-title":["Transfusion and Apheresis Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147305022200009X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S147305022200009X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T08:53:38Z","timestamp":1761468818000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S147305022200009X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":41,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S147305022200009X"],"URL":"https:\/\/doi.org\/10.1016\/j.transci.2022.103359","relation":{},"ISSN":["1473-0502"],"issn-type":[{"value":"1473-0502","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of transfusion-outcome in patients with massive bleeding receiving pathogen-reduced platelets prepared with two different technologies","name":"articletitle","label":"Article Title"},{"value":"Transfusion and Apheresis Science","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.transci.2022.103359","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"103359"}}